SCHEMBL3717488

SCHEMBL3717488

Cc1ccc(-c2cc(C(=O)O)cc(-c3cn[nH]c3)c2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DHODH Q02127 1/20 0.52
ROCK2 O75116 7/20 0.49
LRRK2 Q5S007 1/20 0.48
CTRC Q99895 1/20 0.48
ALPL P05186 1/20 0.47
RXRA P19793 1/20 0.46
RXRB P28702 1/20 0.46
AKT1 P31749 1/20 0.46
AKT2 P31751 1/20 0.46
FABP1 P07148 1/20 0.44
P2RY14 Q15391 1/20 0.44
MAP4K4 O95819 1/20 0.44
NOTUM Q6P988 1/20 0.42
MAPK1 P28482 1/20 0.42
MAP2K4 P45985 1/20 0.42
MAPKAPK3 Q16644 1/20 0.42
MAPK6 Q16659 1/20 0.42
ALDH1A1 P00352 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
ACVR1 Q04771 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3506781 0.84 AKT1 (0.48) DHODHROCK2AKT1AKT2NOTUM
SCHEMBL16196117 0.82 DHODH (0.70) DHODHCTRCALPLRXRARXRB
SCHEMBL17442798 0.81 ROCK2 (0.59) ROCK2AKT1AKT2
SCHEMBL15504532 0.80 AKT2 (0.61) ROCK2LRRK2AKT1AKT2ACVR1
SCHEMBL844167 0.80 AKT2 (0.61) ROCK2LRRK2AKT1AKT2ACVR1
SCHEMBL1495453 0.79 DHODH (0.70) DHODHCTRCALPLRXRARXRB
SCHEMBL3474984 0.78 MAP4K4 (0.55) DHODHCTRCRXRARXRBFABP1
SCHEMBL3474997 0.78 DHODH (0.54) DHODHCTRCALPLRXRARXRB
SCHEMBL3474973 0.76 DHODH (0.59) DHODHCTRCALPLRXRARXRB
SCHEMBL16195442 0.75 RXRA (0.60) DHODHCTRCRXRARXRBFABP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9896439-B2 Pyrazole-substituted arylamides as P2X3 and P2X2/3 antagonists ROCHE PALO ALTO LLC (US) 2018-02-20 US disclosed
US-20170096416-A1 PYRAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS ROCHE PALO ALTO LLC (US) 2017-04-06 US disclosed
US-20130289025-A1 PYRAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS ROCHE PALO ALTO LLC (US) 2013-10-31 US disclosed
US-8440673-B2 Pyrazole-substituted arylamides as P2X3 and P2X2/3 antagonists ROCHE PALO ALTO LLC (US) 2013-05-14 US disclosed
EP-2234976-B1 NOVEL PYRAZOLE-SUBSTITUTED ARYLAMIDES HOFFMANN LA ROCHE (CH) 2013-04-10 EP disclosed
EP-2234976-A1 NOVEL PYRAZOLE-SUBSTITUTED ARYLAMIDES F. Hoffmann-La Roche AG (CH) 2010-10-06 EP disclosed
US-20090170873-A1 Pyrazole-substituted arylamides as P2X3 and P2X2/3 antagonists ROCHE PALO ALTO LLC 2009-07-02 US disclosed
WO-2009077367-A1 NOVEL PYRAZOLE-SUBSTITUTED ARYLAMIDES F. HOFFMANN-LA ROCHE AG (CH) 2009-06-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170873-A1 Pyrazole-substituted arylamides as P2X3 and P2X2/3 antagonists P2RX3, P2RX2, P2RX7 DHODH 3505/4885ROCK2 4341/4885LRRK2 1720/4885
US-20130289025-A1 PYRAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS P2RX3, P2RX2, P2RX7 DHODH 3505/4885ROCK2 4341/4885LRRK2 1720/4885
US-20170096416-A1 PYRAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS P2RX3, P2RX2, P2RX7 DHODH 3505/4885ROCK2 4341/4885LRRK2 1720/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.